These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. A renal mass in the setting of a nonrenal malignancy. When is a renal tumor biopsy appropriate? Marshall FF J Urol; 2005 Sep; 174(3):868. PubMed ID: 16093974 [No Abstract] [Full Text] [Related]
44. What do we need for eradicating kidney cancer cells? Oya M Int J Urol; 2012 Feb; 19(2):96-7. PubMed ID: 22168349 [No Abstract] [Full Text] [Related]
50. Tubulocystic carcinoma of the kidney. MacLennan GT; Cheng L J Urol; 2011 Jun; 185(6):2348-9. PubMed ID: 21511285 [No Abstract] [Full Text] [Related]
51. Spontaneous regression of primary renal cell carcinoma--a case report. Choi SK; Chang SK; Lee JM; Jung WH; Park CI Yonsei Med J; 1986; 27(4):314-7. PubMed ID: 3564545 [No Abstract] [Full Text] [Related]
52. Editorial comment. Liu JJ; Gonzalgo ML J Urol; 2011 Jan; 185(1):35-6. PubMed ID: 21074209 [No Abstract] [Full Text] [Related]
53. Grading renal cell carcinoma: the International Society of Urological Pathology grading system. Humphrey PA J Urol; 2014 Mar; 191(3):798-9. PubMed ID: 24345438 [No Abstract] [Full Text] [Related]
54. [Medical perspectives of metabolomics: the example of renal carcinoma]. Dormoy V; Massfelder T Med Sci (Paris); 2013 May; 29(5):463-8. PubMed ID: 23732093 [No Abstract] [Full Text] [Related]
55. An easy model for prediction of human renal clear cell carcinoma: curve fitting for three kidney tumors observed for over 10 years. Yao L; Zhang L; Li X; He Z; Zhou L Chin Med J (Engl); 2014; 127(4):782-3. PubMed ID: 24534241 [No Abstract] [Full Text] [Related]
56. [Studies of cytofluorometric DNA determination and chemosensitivity of KN-41 renal cancer cells in exponential and plateau phases]. Nishino A Nihon Hinyokika Gakkai Zasshi; 1985 Sep; 76(9):1368-80. PubMed ID: 4087630 [No Abstract] [Full Text] [Related]